Publication
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (12)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 12
- cancerChildhood Acute Lymphoblastic Leukemiacivic_curation1.00
- drugCytarabinecivic_curation1.00
- drugDoxorubicincivic_curation1.00
- drugGemcitabinecivic_curation1.00
- drugMercaptopurinecivic_curation1.00
- drugPrednisolonecivic_curation1.00
- drugThioguaninecivic_curation1.00
- geneNT5C2civic_curation1.00
- variantNT5C2 Mutationcivic_curation1.00
- variantNT5C2 R238Wcivic_curation1.00
- variantNT5C2 R367Qcivic_curation1.00
- variantNT5C2 S445Fcivic_curation1.00
Curated evidence
Evidence citing this paper (10)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23377183
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NT5C2 Mutation1 | ||||||||
| (prognostic) | Childhood Acute Lymphoblastic LeukemiaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7818Within a cohort of 71 pediatric B-ALL relapse cases, all 7 patients with NT5C2 mutations detected at relapse demonstrated early relapse (<36 months from initial diagnosis) with a median time to relaps… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| NT5C2 R238W3 | ||||||||
| (prognostic) | Childhood Acute Lymphoblastic LeukemiaALIAS | Prognostic | C | Supports Poor Outcome | 2 | accepted | EID786371 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed 3 early relapse cases with NT5C2 R238W enrich… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Cytarabine + Doxorubicin + Gemcitabine + PrednisoloneSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Does Not Support Resistance | 4 | accepted | EID7816Overexpression of NT5C2 R238W in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis. PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Mercaptopurine + ThioguanineSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Supports Resistance | 4 | accepted | EID7813Lentiviral-mediated overexpression of NT5C2 R238W in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| NT5C2 R367Q3 | ||||||||
| Cytarabine + Doxorubicin + Gemcitabine + PrednisoloneSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Does Not Support Resistance | 4 | accepted | EID7815Lentiviral mediated overexpression of NT5C2 R367Q in Reh cells resulted in no change in apoptosis after exposure to cytarabine, gemcitabine, doxorubicin, or prednisolone compared to wildtype NT5C2 ove… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Mercaptopurine + ThioguanineSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | C | Supports Resistance | 2 | accepted | EID781271 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 R367Q enrich… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| 〃 | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Supports Resistance | 4 | accepted | EID7862Lentiviral-mediated overexpression of NT5C2 R367Q in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| NT5C2 S445F3 | ||||||||
| (prognostic) | Childhood Acute Lymphoblastic LeukemiaALIAS | Prognostic | C | Supports Poor Outcome | 2 | accepted | EID786471 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 S445F enrich… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Cytarabine + Doxorubicin + Gemcitabine + PrednisoloneSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Does Not Support Resistance | 4 | accepted | EID7817Overexpression of NT5C2 S445F in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis. PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Mercaptopurine + ThioguanineSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Supports Resistance | 4 | accepted | EID7814Lentiviral-mediated overexpression of NT5C2 S445F in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |